

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: January 6, 2011 <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b> Application Number 09/762,550 Filing Date 8/23/1999 First Named Inventor Akihiro Funakoshi Art Unit 1647 Examiner Name Lorraine Spector Attorney Docket Number 053466-0299		
Sheet	1	of	1		



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	F1	Alsfasser et al., "Decreased Inflammation and Improved Survival With Recombinant Human Activated Protein C Treatment in Experimental Acute Pancreatitis," (Reprinted) Arch. Surg., July 2006, 141:670-676.			
	F2	Bellomo, R., "The Cytokine Network in the Critically Ill," Anaesthesia and Intensive Care, August 1992, 20(3):288-302.			
	F3	Grewal et al., "Amelioration of the Physiologic and Biochemical Changes of Acute Pancreatitis Using an Anti-TNF- $\alpha$ Polyclonal Antibody," American Journal of Surgery, January 1994, 167:214-219.			
	F4	Gukovsky et al., "A rat model reproducing key pathological responses of alcoholic chronic pancreatitis," Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 294:68-79, first published September 20, 2007.			
	F5	Michalski et al., "Cannabinoids Ameliorate Pain and Reduce Disease Pathology in Cerulein-Induced Acute Pancreatitis," Gastroenterology, May 2007, 132(5):1968-1978.			
	F6	Mukaida et al., "Cytokines and the Immune Network," Clinical Test, May 1991, 35(5):447-452, with English translation, 14 pages.			✓
	F7	<del>Tito et al., "Peptide YY ameliorates cerulein-induced pancreatic injury in the rat," Am. J. Surg., June 1993, 166(6):690-698.</del>			
		No copy found			
	F8	Yamaguchi et al., "Risperidone Attenuates Local and Systemic Inflammatory Responses to Ameliorate Diet-Induced Severe Necrotic Pancreatitis in Mice: It May Provide a New Therapy for Acute Pancreatitis," J. Pharmacology and Experimental Therapeutics, 2009, 328(1):256-262.			

Examiner Signature	/Lorraine Spector/	Date Considered	03/17/2011
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.S./